105 related articles for article (PubMed ID: 27431260)
1. Effects of active bufadienolide compounds on human cancer cells and CD4+CD25+Foxp3+ regulatory T cells in mitogen-activated human peripheral blood mononuclear cells.
Yuan B; He J; Kisoh K; Hayashi H; Tanaka S; Si N; Zhao HY; Hirano T; Bian B; Takagi N
Oncol Rep; 2016 Sep; 36(3):1377-84. PubMed ID: 27431260
[TBL] [Abstract][Full Text] [Related]
2. [Influence of regulatory T cells on the functioning of natural killer cells during cancer immunotherapy].
Chikileva IO; Shubina IZh; Kiselevskiĭ MV
Vestn Ross Akad Med Nauk; 2012; (4):60-4. PubMed ID: 22834330
[TBL] [Abstract][Full Text] [Related]
3. Forced overexpression of either of the two common human Foxp3 isoforms can induce regulatory T cells from CD4(+)CD25(-) cells.
Aarts-Riemens T; Emmelot ME; Verdonck LF; Mutis T
Eur J Immunol; 2008 May; 38(5):1381-90. PubMed ID: 18412171
[TBL] [Abstract][Full Text] [Related]
4. CD4+Foxp3+ regulatory T cells converted by rapamycin from peripheral CD4+CD25(-) naive T cells display more potent regulatory ability in vitro.
Chen JF; Gao J; Zhang D; Wang ZH; Zhu JY
Chin Med J (Engl); 2010 Apr; 123(7):942-8. PubMed ID: 20497692
[TBL] [Abstract][Full Text] [Related]
5. Effects of arsenic disulfide on proliferation, cytokine production, and frequencies of CD4(+), CD8(+), and regulatory T cells in mitogen-activated human peripheral blood mononuclear cells.
Song MM; Fang S; Tanaka S; Sugiyama K; Kiyomi A; Kato R; Onda K; Yuan B; Takagi N; Hu X; Hirano T
Int Immunopharmacol; 2015 Dec; 29(2):832-838. PubMed ID: 26359544
[TBL] [Abstract][Full Text] [Related]
6. Influence of anticancer agents on cell survival, proliferation, and CD4+CD25+Foxp3+ regulatory T cell-frequency in human peripheral-blood mononuclear cells activated by T cell-mitogen.
Tohyama N; Tanaka S; Onda K; Sugiyama K; Hirano T
Int Immunopharmacol; 2013 Jan; 15(1):160-6. PubMed ID: 23178575
[TBL] [Abstract][Full Text] [Related]
7. The prevalence of FOXP3+ regulatory T-cells in peripheral blood of patients with NSCLC.
Li L; Chao QG; Ping LZ; Xue C; Xia ZY; Qian D; Shi-ang H
Cancer Biother Radiopharm; 2009 Jun; 24(3):357-67. PubMed ID: 19538059
[TBL] [Abstract][Full Text] [Related]
8. N-Ras or K-Ras inhibition increases the number and enhances the function of Foxp3 regulatory T cells.
Mor A; Keren G; Kloog Y; George J
Eur J Immunol; 2008 Jun; 38(6):1493-502. PubMed ID: 18461565
[TBL] [Abstract][Full Text] [Related]
9. Dexamethasone upregulates FOXP3 expression without increasing regulatory activity.
Prado C; Gómez J; López P; de Paz B; Gutiérrez C; Suárez A
Immunobiology; 2011 Mar; 216(3):386-92. PubMed ID: 20667622
[TBL] [Abstract][Full Text] [Related]
10. Cytocidal effects of arenobufagin and hellebrigenin, two active bufadienolide compounds, against human glioblastoma cell line U-87.
Han L; Yuan B; Shimada R; Hayashi H; Si N; Zhao HY; Bian B; Takagi N
Int J Oncol; 2018 Dec; 53(6):2488-2502. PubMed ID: 30272276
[TBL] [Abstract][Full Text] [Related]
11. Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels.
Zhao J; Cao Y; Lei Z; Yang Z; Zhang B; Huang B
Cancer Res; 2010 Jun; 70(12):4850-8. PubMed ID: 20501849
[TBL] [Abstract][Full Text] [Related]
12. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
[TBL] [Abstract][Full Text] [Related]
13. Low-dose splenic radiation inhibits liver tumor development of rats through functional changes in CD4+CD25+Treg cells.
Wang B; Li B; Dai Z; Ren S; Bai M; Wang Z; Li Z; Lin S; Wang Z; Huang N; Yang P; Liu M; Min W; Ma H
Int J Biochem Cell Biol; 2014 Oct; 55():98-108. PubMed ID: 25168696
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs.
Bocian K; Borysowski J; Wierzbicki P; Wyzgal J; Klosowska D; Bialoszewska A; Paczek L; Górski A; Korczak-Kowalska G
Nephrol Dial Transplant; 2010 Mar; 25(3):710-7. PubMed ID: 19903662
[TBL] [Abstract][Full Text] [Related]
15. The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice.
Qu Y; Zhang B; Zhao L; Liu G; Ma H; Rao E; Zeng C; Zhao Y
Transpl Immunol; 2007 Apr; 17(3):153-61. PubMed ID: 17331841
[TBL] [Abstract][Full Text] [Related]
16. Demonstration of circulating allergen-specific CD4+CD25highFoxp3+ T-regulatory cells in both nonatopic and atopic individuals.
Maggi L; Santarlasci V; Liotta F; Frosali F; Angeli R; Cosmi L; Maggi E; Romagnani S; Annunziato F
J Allergy Clin Immunol; 2007 Aug; 120(2):429-36. PubMed ID: 17604089
[TBL] [Abstract][Full Text] [Related]
17. Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells.
Khan S; Burt DJ; Ralph C; Thistlethwaite FC; Hawkins RE; Elkord E
Clin Immunol; 2011 Jan; 138(1):85-96. PubMed ID: 21056008
[TBL] [Abstract][Full Text] [Related]
18. Neutralization of interleukin-10 or transforming growth factor-β decreases the percentages of CD4+ CD25+ Foxp3+ regulatory T cells in septic mice, thereby leading to an improved survival.
Hiraki S; Ono S; Tsujimoto H; Kinoshita M; Takahata R; Miyazaki H; Saitoh D; Hase K
Surgery; 2012 Feb; 151(2):313-22. PubMed ID: 21982068
[TBL] [Abstract][Full Text] [Related]
19. Effects of vitamin K3 and K5 on proliferation, cytokine production, and regulatory T cell-frequency in human peripheral-blood mononuclear cells.
Hatanaka H; Ishizawa H; Nakamura Y; Tadokoro H; Tanaka S; Onda K; Sugiyama K; Hirano T
Life Sci; 2014 Mar; 99(1-2):61-8. PubMed ID: 24503338
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of CD4+CD25+ regulatory T cells may underlie enhanced Th1 immunity caused by immunization with activated autologous T cells.
Cao Q; Wang L; Du F; Sheng H; Zhang Y; Wu J; Shen B; Shen T; Zhang J; Li D; Li N
Cell Res; 2007 Jul; 17(7):627-37. PubMed ID: 17563757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
